Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Paul T HeathEva P GalizaDavid N BaxterMarta BoffitoDuncan BrowneFiona BurnsDavid R ChadwickRebecca ClarkCatherine CosgroveJames GallowayAnna L GoodmanAmardeep HeerAndrew HighamShalini IyengarArham JamalChristopher JeanesPhilip A KalraChristina KyriakidouDaniel F McAuleyAgnieszka MeyrickAngela M MinassianJane MintonPatrick MooreImrozia MunsoorHelen NichollsOrod OsanlouJonathan PackhamCarol H PretswellAlberto San Francisco RamosDinesh SaralayaRay P SheridanRichard SmithRoy L SoizaPauline A SwiftEmma C ThomsonJeremy TurnerMarianne E ViljoenGary AlbertIksung ChoFilip DubovskyGreg GlennJoy RiversAndreana RobertsonKathy SmithSeth Tobacknull nullPublished in: The New England journal of medicine (2021)
A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. (Funded by Novavax; EudraCT number, 2020-004123-16.).